HilleVax, Inc. (NASDAQ:HLVX) Director Sells $10,230.45 in Stock

Posted by Simon Gomez on May 4th, 2024

HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) Director Aditya Kohli sold 723 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $14.15, for a total transaction of $10,230.45. Following the sale, the director now owns 782,878 shares of the company’s stock, valued at approximately $11,077,723.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Aditya Kohli also recently made the following trade(s):

On Wednesday, May 1st, Aditya Kohli sold 175 shares of HilleVax stock. The shares were sold at an average price of $14.03, for a total transaction of $2,455.25.
On Friday, April 5th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.44, for a total value of $86,640.00.
On Wednesday, April 3rd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.93, for a total value of $89,580.00.
On Wednesday, March 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $164,221.00, for a total value of $985,326,000.00.
On Monday, March 18th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $17.66, for a total transaction of $105,960.00.
On Friday, March 8th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.66, for a total transaction of $111,960.00.
On Wednesday, March 6th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.95, for a total transaction of $113,700.00.
On Thursday, February 22nd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.05, for a total transaction of $90,300.00.
On Tuesday, February 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.88, for a total value of $89,280.00.
On Monday, February 12th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.32, for a total value of $91,920.00.

HilleVax Price Performance

Shares of HilleVax stock traded down $0.41 on Friday, reaching $13.61. 62,071 shares of the stock were exchanged, compared to its average volume of 137,172. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.62 and a current ratio of 10.62. The firm has a market cap of $676.69 million, a PE ratio of -4.60 and a beta of 0.79. The firm’s 50 day moving average is $15.67 and its 200-day moving average is $14.65. HilleVax, Inc. has a one year low of $9.94 and a one year high of $20.22.

HilleVax (NASDAQ:HLVX – Get Free Report) last released its earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.02. As a group, analysts anticipate that HilleVax, Inc. will post -3.22 EPS for the current fiscal year.

Institutional Trading of HilleVax

Several large investors have recently bought and sold shares of the business. Catalys Pacific LLC acquired a new position in HilleVax during the fourth quarter worth about $21,009,000. Deerfield Management Company L.P. Series C lifted its stake in HilleVax by 20.3% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,004,231 shares of the company’s stock valued at $53,857,000 after purchasing an additional 675,000 shares during the last quarter. Acuta Capital Partners LLC boosted its position in HilleVax by 328.5% in the third quarter. Acuta Capital Partners LLC now owns 270,319 shares of the company’s stock valued at $3,636,000 after buying an additional 207,241 shares in the last quarter. Braidwell LP grew its stake in shares of HilleVax by 16.0% during the third quarter. Braidwell LP now owns 1,449,246 shares of the company’s stock worth $19,492,000 after buying an additional 200,000 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of HilleVax during the third quarter worth $2,374,000. 86.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $28.00 target price on shares of HilleVax in a report on Thursday, March 21st.

Read Our Latest Report on HLVX

About HilleVax

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.